1. Home
  2. ZJYL vs NBP Comparison

ZJYL vs NBP Comparison

Compare ZJYL & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JIN MEDICAL INTERNATIONAL LTD.

ZJYL

JIN MEDICAL INTERNATIONAL LTD.

N/A

Current Price

$2.36

Market Cap

145.9M

ML Signal

N/A

NBP

NovaBridge Biosciences American Depositary Shares

N/A

Current Price

$1.20

Market Cap

149.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ZJYL
NBP
Founded
2006
2014
Country
China
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
145.9M
149.2M
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
ZJYL
NBP
Price
$2.36
$1.20
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $9.00
AVG Volume (30 Days)
12.2K
★ 417.1K
Earning Date
08-04-2026
08-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$18.40
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.10
$1.19
52 Week High
$4.50
$5.19

Technical Indicators

Market Signals
Indicator
ZJYL
NBP
Relative Strength Index (RSI) 60.01 34.10
Support Level $1.91 N/A
Resistance Level $2.59 $1.45
Average True Range (ATR) 0.21 0.09
MACD 0.01 -0.00
Stochastic Oscillator 49.00 14.52

Price Performance

Historical Comparison
ZJYL
NBP

About ZJYL JIN MEDICAL INTERNATIONAL LTD.

Jin Medical International Ltd, along with its subsidiaries, mainly offers rehabilitation equipment. It is engaged in the design, development, manufacturing, and sales of wheelchairs and other assistive living aid products for use by people with disabilities or impaired mobility. The group's product offering includes wheelchairs and wheelchair components, oxygen concentrators, bathing machines, respiratory and walking aids, oxygen chambers, beauty instruments, and nano products, among others. Wheelchairs are currently its key revenue-generating product. The products are sold to dealers in Japan and China, and to some extent to dealers located in the United States, Canada, Australia, Korea, Israel, Singapore, and other regions. Geographically, the group generates maximum revenue from Japan.

About NBP NovaBridge Biosciences American Depositary Shares

NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.

Share on Social Networks: